Plaque Psoriasis: Global Drug Forecast and Market Analysis to 2030

Powered by

All the vital news, analysis, and commentary curated by our industry experts.

The global plaque psoriasis (PsO) market was valued at $14.2 billion in 2020 and is projected to record a growth of more than 6% during the forecast period 2021-2030. The major growth drivers of the global PsO market are new product launches, a steady increase in total diagnosed prevalence across the 7MM, and increased treatment options for mild and moderate patients. The major barriers to growth in the PsO market during the forecast period include loss of patent expiry and key biosimilar launches of gold-standard biologics and the launch of apremilast generics.

Global plaque psoriasis market overview

Global plaque psoriasis market overview

For more insights on this report, download a free report sample

What are the market dynamics in the global plaque psoriasis market?

The PsO affects both sexes and all races, ethnicities, and ages. However, the disease is more prevalent in adults than children. The prevalence of PsO also varies geographically and is more prevalent in countries with higher incomes and regions with older populations. Differences in the reported prevalence between countries may be due to variations in environmental factors and genetic factors. Compared to adults, the pediatric prevalence of PsO in the 7MM was much lower, with 0.17% of boys and 0.24% of girls receiving a diagnosis. The disparity in prevalence between children and adults was observed across all markets. Among children, Japan had the lowest prevalence of PsO in boys. In comparison, France had the highest estimated prevalence with 0.44%, while in girls, the prevalence ranged from 0.06% in Japan to 0.83% in France.

In addition, In the 7MM, the lifetime diagnosed prevalent cases of PsO will increase. In 2020, the US accounted for 47% of lifetime diagnosed prevalent cases of PsO in the 7MM, with 7,477,120 cases, in men and women. Among the 5EU markets, Germany had the greatest number of prevalent cases with 1,747,675 cases, contributing over 10% of lifetime diagnosed prevalent cases of PsO in the 7MM. Conversely, Spain had the lowest number of prevalent cases with 926,456 cases, contributing to over 4% of lifetime diagnosed prevalent cases in 7MM. In 2020, Japan accounted for the lowest percentage of diagnosed prevalent cases of PsO in the 7MM, resulting in 470,089 cases. However, cases in Japan are expected to grow at an Annual Growth Rate (AGR) of over 0.05% to 473,815 cases in 2030. Of the 7MM, the US is expected to see the most significant growth from 7,477,120 lifetimes diagnosed prevalent cases in 2020 to 8,171,859 cases in 2030, occurring at an AGR of over 0.5%. Germany is the only country in the 7MM where cases will decrease between 2020 and 2030, with an ARG of negative 0.04%. This decrease will result in 1,739,834 cases in 2030, down from 1,747,675 cases in 2020. Within the 5EU, France had the highest number of lifetimes diagnosed with prevalent cases of PsO with 2,107,634 cases, while Spain had the fewest with 926,456 cases. In 2030, France will continue to have the most lifetime diagnosed prevalent cases of PsO in the 5EU with 2,185,493 cases, after growing at an AGR of over 0.30%. Likewise, Spain will continue to have the fewest lifetime diagnosed prevalent cases of PsO with 943,870 cases after growing at an AGR of 0.19%.

Which are the key countries in the global plaque psoriasis market?

The US is the largest PsO market, representing over 79% of 2020 global sales. The most notable factor limiting the growth of the market is the loss of several key biologic patents (and anticipated biosimilar launches) across several different classes. Although similar dynamics are expected to be at play for IL-17 inhibitors Cosentyx (secukinumab) and Taltz (ixekizumab), both drugs are expected to remain on patent until the second half of the forecast period, which protects their growth potential for much of the forecast. Additionally, three new IL-17 inhibitors are expected to launch in this market: UCB Pharma’s Bimzelx (bimekizumab), Merck’s sonelokimab, and Affibody’s ABY-035/izokibep. With these factors in mind, the IL-17 inhibitor class sales are expected to grow at a CAGR of over 11%, with combined 2030 sales of over $7 billion. In addition, Combined, the 5EU (France, Germany, Italy, Spain, and the UK) comprised of over 12% of 2020 global sales, with a combined valuation. Across the 5EU, Germany emerged as the highest-grossing country by value in 2020, with estimated PsO sales of over $600 million, followed by the UK, Italy, Spain, and lastly France. Germany is anticipated to remain the highest-grossing market in the 5EU in 2030, generating sales of over $1 billion followed by the UK, Italy, Spain, and lastly France.

Global plaque psoriasis market, by key country

Global plaque psoriasis market, by key country

For more regional insights, download a free report sample

Which are the major players in the global plaque psoriasis market?

The major players in the global plaque psoriasis market are AbbVie, Pfizer, Johnson & Johnson (J&J), Bristol-Myers Squibb, UCB Pharma, Amgen, Novartis, Eli Lilly, Sun Pharma, Dermavant, Dr. Reddy’s Laboratories, Arcutis Biotherapeutics, Affibody, Merck, and Can-Fite BioPharma.

Global plaque psoriasis market, by key players

Global plaque psoriasis market, by key players

To know more about key players, download a free report sample

Market report scope

Market value (Year-2020) $14.2 billion
Growth rate (CAGR) >6%
Base year for estimation 2020
Forecast period 2021-2030
Key Players AbbVie, Pfizer, Johnson & Johnson (J&J), Bristol-Myers Squibb, UCB Pharma, Amgen, Novartis, Eli Lilly, Sun Pharma, Dermavant, Dr. Reddy’s Laboratories, Arcutis Biotherapeutics, Affibody, Merck, and Can-Fite BioPharma

Scope

  • Overview of PsO including epidemiology, etiology, pathophysiology, symptoms, diagnosis, and treatment guidelines.
  • Topline PsO market revenue, the annual cost of therapy, and major pipeline product sales in the forecast period.
  • Key topics covered include current treatment and pipeline therapies, unmet needs and opportunities, and the drivers and barriers affecting PsO therapeutics sales in the 7MM.
  • Pipeline analysis: Comprehensive data split across different phases, emerging novel trends under development, and detailed analysis of late-stage pipeline drugs.
  • Analysis of the current and future market competition in the global PsO therapeutics market. Insightful review of the key industry drivers, restraints, and challenges. Each trend is independently researched to provide a qualitative analysis of its implications.

Key Highlights

  • The greatest drivers of growth in the global PsO market include the launch of eight new pipeline therapies during the forecast period and a steadily climbing diagnosed prevalence in many 7MM countries.
  • The main barriers to growth in the PsO market include the patent expiration of several key biologics and small molecules.
  • Among the late-stage innovator pipeline products, three are injectable biologics, three are oral small molecules, and two are topical small molecules.
  • The most important unmet needs in the PsO market are increased access to therapies as well as therapies that can target multiple disease domains.

Reasons to Buy

  • Develop and design your in-licensing and out-licensing strategies, using a detailed overview of current pipeline products and technologies to identify companies with the most robust pipelines.
  • Develop business strategies by understanding the trends shaping and driving the global PsO therapeutics market.
  • Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global PsO market in the future.
  • Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
  • Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
  • Track drug sales in the global PsO therapeutics market from 2020-2030.
  • Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments, and strategic partnerships.

AbbVie
Pfizer
Johnson & Johnson (J&J)
Bristol-Myers Squibb
UCB Pharma
Amgen
Novartis
Eli Lilly
Sun Pharma
Dermavant
Arcutis Biotherapeutics
Merck
Dr. Reddy’s Laboratories
Affibody
Can-Fite BioPharma

Table of Contents

| Contents

| List of Tables

| List of Figures

| About GlobalData

1 Plaque Psoriasis: Executive Summary

1.1 PsO Market to Experience Conservative Growth from 2020–2030

1.2 New Players to Enter a Saturated Field

1.3 Opportunities Remain for Undertreated Patient Populations

1.4 Innovator Small Molecules Dominate the Late-Stage Pipeline

1.5 What Do Physicians Think?

2 Introduction

2.1 Catalyst

2.2 Related Reports

2.3 Upcoming Reports

3 Disease Overview

3.1 Etiology and Pathophysiology

3.1.1 Etiology

3.1.2 Pathophysiology

4 Epidemiology

4.1 Disease Background

4.2 Risk Factors and Comorbidities

4.3 Global and Historical Trends

4.4 Forecast Methodology

4.4.1 Sources Used

4.4.2 Forecast Assumptions and Methods

4.5 Epidemiological Forecast for PsO (2020–2030)

4.5.1 Lifetime Diagnosed Prevalent Cases of PsO

4.5.2 Age–Specific Lifetime Diagnosed Prevalent Cases of PsO

4.5.3 Sex-Specific Lifetime Diagnosed Prevalent Cases of PsO

4.5.4 Lifetime Diagnosed Prevalent Cases of PsO by Severity in the Adult Population

4.5.5 Lifetime Diagnosed Prevalent Cases of PsO with PsA in the Adult Population

4.6 Discussion

4.6.1 Epidemiological Forecast Insight

4.6.2 COVID-19 Impact

4.6.3 Limitations of Analysis

4.6.4 Strengths of Analysis

5 Disease Management

5.1 Diagnosis

5.2 Treatment

5.2.1 Impact of COVID-19

6 Competitive Assessment

6.1 Overview

6.1.1 TNF Inhibitors

6.1.2 IL-17 Inhibitors

6.1.3 IL-23 Inhibitors

6.1.4 Other Disease Modifying Therapies

6.2 Biosimilars

7 Unmet Needs and Opportunity Assessment

7.1 Overview

7.2 Cost-Effective Therapies

7.3 Efficacious Therapies for Treatment Refractory Patients

7.4 Lack of Innovative Topical Therapies

7.5 Treatment Options for Mild PsO Patients

8 R&D Strategies

8.1 Overview

8.1.1 Development Shift Away from Injectable Biologics

8.1.2 New Players Enter the Late-Stage Pipeline

8.2 Clinical Trials Design

8.2.1 Robust Clinical Endpoints

8.2.2 Long-Term Patient Follow-Up

8.2.3 Active Comparator Trials

9 Pipeline Assessment

9.1 Overview

9.2 Promising Drugs in Clinical Development

9.2.1 Bimzelx (bimekizumab)

9.2.2 Sonelokimab/M1095

9.2.3 ABY-035/izokibep

9.2.4 Tapinarof/DMVT-505

9.2.5 Roflumilast

9.2.6 Deucravacitinib

9.2.7 Piclidenoson

9.2.8 Tepilamide fumarate

9.3 Other Drugs of Note

9.3.1 Mirikizumab

9.3.2 Brepocitinib tosylate

10 Pipeline Valuation Analysis

10.1 Overview

10.2 Competitive Assessment

10.2.1 Biologic Medications

10.2.2 Small Molecule Therapeutics

11 Current and Future Players

11.1 Overview

11.2 Deal-Making Trends

12 Market Outlook

12.1 Global Markets

12.1.1 Forecast

12.1.2 Drivers and Barriers – Global Issues

12.2 US

12.2.1 Forecast

12.2.2 Key Events

12.2.3 Drivers and Barriers

12.3 5EU

12.3.1 Forecast

12.3.2 Key Events

12.3.3 Drivers and Barriers

12.4 Japan

12.4.1 Forecast

12.4.2 Key Events

12.4.3 Drivers and Barriers

13 Appendix

13.1 Bibliography

13.2 Abbreviations

13.3 Methodology

13.3.1 Forecasting Methodology

13.4 Primary Research – KOLs and Payors Interviewed for This Report

13.4.1 KOLs

13.4.2 Payors

13.5 Primary Research – Prescriber Survey

13.6 About the Authors

13.6.1 Analyst

13.6.2 Managing Analyst

13.6.3 Therapy Area Director

13.6.4 Epidemiologist

13.6.5 Reviewers

13.6.6 Global Head and EVP of Healthcare Operations and Strategy

| Contact Us

Table

Table 1: Plaque Psoriasis: Key Metrics in the 7MM

Table 2: Risk Factors and Comorbidities for PsO

Table 3: Classification of PsO by BSA

Table 4: Treatment Guidelines for Plaque Psoriasis

Table 5: Top Completed Deals in PsO Market by Value, 2016–2021

Table 6: PsO Market – Global Drivers and Barriers, 2020–2030

Table 7: Key Events Impacting Sales for PsO in the US, 2020–2030

Table 8: PsO Market – Drivers and Barriers in the US, 2020–2030

Table 9: Key Events Impacting Sales for PsO in the 5EU, 2020–2030

Table 10: PsO Market – Drivers and Barriers in the 5EU, 2020–2030

Table 11: Key Events Impacting Sales for PsO in Japan, 2020–2030

Table 12: PsO Market – Drivers and Barriers in Japan, 2020–2030

Table 13: High-Prescribing Physicians (non-KOLs) Surveyed, By Country

Figures

Figure 1: Global Sales Forecast by Country for PsO in 2020 and 2030

Figure 2: Analysis of the Company Portfolio Gap in PsO During the Forecast Period

Figure 3: Competitive Assessment of the Pipeline/Recently Approved Biologic Drugs Benchmarked Against the SOC, Humira

Figure 4: Competitive Assessment of the Pipeline Small Molecules Drugs Benchmarked Against the SOC, Otezla (apremilast)

Figure 5: Biologic Targets in the Treatment of PsO

Figure 6: 7MM, Lifetime Diagnosed Prevalence of Pediatric PsO (%), Boys and Girls, Ages ≤17 Years, 2020

Figure 7: 7MM, Lifetime Diagnosed Prevalence of Adult PsO (%), Men and Women, Ages ≥18 Years, 2020

Figure 8: Sources Used for Lifetime Diagnosed Prevalent Cases of Pediatric PsO

Figure 9: Sources Used and Not Used for Lifetime Diagnosed Prevalent Cases of PsO in Adults

Figure 10: Sources Used for Lifetime Diagnosed Prevalent Cases of PsO by Severity Among Adults

Figure 11: Sources Used for Lifetime Diagnosed Prevalent Cases of PsO with PsA Among Adults

Figure 12: 7MM, Lifetime Diagnosed Prevalent Cases of PsO, Men and Women, All Ages, 2020 (N)

Figure 13: Age-Specific Lifetime Diagnosed Prevalent Cases of PsO, 7MM, Men and Women, 2020 (N)

Figure 14: 7MM, Sex-Specific Lifetime Diagnosed Prevalent Cases of PsO, All Ages, 2020 (N)

Figure 15: 7MM, Lifetime Diagnosed Prevalent Cases of PsO by Severity, Men and Women, ≥18 Years, 2020

Figure 16: 7MM, Lifetime Diagnosed Prevalent Cases of PsO with Psoriatic Arthritis, Men and Women, ≥18 Years, 2020 (N)

Figure 17: Overall Treatment Algorithm for PsO and PsO/PsA

Figure 18: Unmet Needs and Opportunities in PsO

Figure 19: Overview of the Development Pipeline in PsO

Figure 20: Key Late-Stage Trials for the Promising Pipeline Agents that GlobalData Expects to Be Licensed for PsO in the 7MM During the Forecast Period

Figure 21: Competitive Assessment of the Pipeline/Recently Approved Biologic Drugs Benchmarked Against the SOC, Humira (adalimumab)

Figure 22: Competitive Assessment of the Pipeline Small Molecules Drugs Benchmarked Against the SOC, Otezla (apremilast)

Figure 23: Analysis of the Company Portfolio Gap in PsO During the Forecast Period

Figure 24: Global (7MM) Sales Forecast by Country for PsO in 2020 and 2030

Figure 25: Sales Forecast by Class for PsO in the US in 2020 and 2030

Figure 26: Sales Forecast by Class for PsO in the 5EU in 2020 and 2030

Figure 27: Sales Forecast by Class for PsO in Japan in 2020 and 2030

Frequently asked questions

Plaque Psoriasis: Global Drug Forecast and Market Analysis to 2030 thematic reports
Currency USD
$10,995

Can be used by individual purchaser only

$32,985

Can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company


Undecided about purchasing this report?

Enquire Before Buying Request a Free Sample

Get in touch to find out about multi-purchase discounts

reportstore@globaldata.com
Tel +44 20 7947 2745

Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.

Sample Report

Plaque Psoriasis: Global Drug Forecast and Market Analysis to 2030 was curated by the best experts in the industry and we are confident about its unique quality. However, we want you to make the most beneficial decision for your business, so we offer free sample pages to help you:

  • Assess the relevance of the report
  • Evaluate the quality of the report
  • Justify the cost

Download your copy of the sample report and make an informed decision about whether the full report will provide you with the insights and information you need.

Below is a sample report to understand what you are buying

See what our customers are saying

“The GlobalData platform is our go-to tool for intelligence services. GlobalData provides an easy way to access comprehensive intelligence data around multiple sectors, which essentially makes it a one-for-all intelligence platform, for tendering and approaching customers.

GlobalData is very customer orientated, with a high degree of personalised services, which benefits everyday use. The highly detailed project intelligence and forecast reports can be utilised across multiple departments and workflow scopes, from operational to strategic level, and often support strategic decisions. GlobalData Analytics and visualisation solutions has contributed positively when preparing management presentations and strategic papers.”

Business Intelligence & Marketing Manager, SAL Heavy Lift

“COVID-19 has caused significant interference to our business and the COVID-19 intelligence from GlobalData has helped us reach better decisions around strategy. These two highlights have helped enormously to understand the projections into the future concerning our business units, we also utilise the project database to source new projects for Liebherr-Werk to use as an additional source to pitch for new business.”

Market Analyst & Management, Liebherr-Werk

Your daily news has saved me a lot of time and keeps me up-to-date with what is happening in the market, I like that you almost always have a link to the source origin. We also use your market data in our Strategic Business Process to support our business decisions. By having everything in one place on the Intelligence Center it has saved me a lot of time versus looking on different sources, the alert function also helps with this.

Head of Key Accounts, Saab AB

Having used several other market research companies, I find that GlobalData manages to provide that ‘difficult-to-get’ market data that others can’t, as well as very diverse and complete consumer surveys.

Marketing Intelligence Manager, Portugal Foods

Our experience with GlobalData has been very good, from the platform itself to the people. I find that the analysts and the account team have a high level of customer focus and responsiveness and therefore I can always rely on. The platform is more holistic than other providers. It is convenient and almost like a one stop shop. The pricing suite is highly competitive and value for our organisation.

I like reports that inform new segments such as the analysis on generation Z, millennials, the impact of COVID 19 to our banking customers and their new channel habits. Secondly the specialist insight on affluent sector significantly increases our understanding about this group of customers. The combination of those give us depth and breadth of the evolving market.

I’m in the business of answering and helping people make decisions so with the intelligence center I can do that, effectively and efficiently. I can share quickly key insights that answer and satisfy our country stakeholders by giving them many quality studies and primary research about competitive landscape beyond the outlook of our bank. It helps me be seen as an advisory partner and that makes a big difference. A big benefit of our subscription is that no one holds the whole data and because it allows so many people, so many different parts of our organisation have access, it enables all teams to have the same level of knowledge and decision support.

Head of Customer Insight and Research, Standard Chartered

“I know that I can always rely on Globaldata’s work when I’m searching for the right consumer and market insights. I use Globaldata insights to understand the changing market & consumer landscape and help create better taste & wellbeing solutions for our customers in food, beverage and healthcare industries.

Globaldata has the right data and the reports are of very high quality compared to your competitors. Globaldata not only has overall market sizes & consumer insights on food & beverages but also provides insights at the ingredient & flavour level. That is key for B2B companies like Givaudan. This way we understand our customers’ business and also gain insight to our unique industry”

Head of Consumer Sensory Insights, Givaudan

GlobalData provides a great range of information and reports on various sectors that is highly relevant, timely, easy to access and utilise.  The reports and data dashboards help engagement with clients; they provide valuable industry and market insights that can enrich client conversations and can help in the shaping of value propositions. Moreover, using GlobalData products has helped increase my knowledge of the finance sector, the players within it, and the general threats and opportunities.

I find the consumer surveys that are carried out to be extremely beneficial and not something I have seen anywhere else. They provided an insightful view of why and which consumers take (or don’t) particular financial products. This can help shape conversations with clients to ensure they make the right strategic decisions for their business.

One of the challenges I have found is that data in the payments space is often piecemeal. With GD all of the data I need is in one place, but it also comes with additional market reports that provide useful extra context and information. Having the ability to set-up alerts on relevant movements in the industry, be it competitors or customers, and have them emailed directly to me, ensures I get early sight of industry activity and don’t have to search for news.

Senior Account Manager, TSYS
Go even deeper with GlobalData Intelligence Center

Every Company Report we produce is powered by the GlobalData Intelligence Center.

Subscribing to our intelligence platform means you can monitor developments at Plaque Psoriasis: Global Drug Forecast and Market Analysis to 2030 in real time.

  • Access a live Plaque Psoriasis: Global Drug Forecast and Market Analysis to 2030 dashboard for 12 months, with up-to-the-minute insights.
  • Fuel your decision making with real-time deal coverage and media activity.
  • Turn insights on financials, deals, products and pipelines into powerful agents of commercial advantage.